Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/IIa open-label single-arm study of DX1002 tablets in advanced hepatocellular carcinoma or gastric cancer
CTR20200996Phase 2Active
- Sponsor
- 东莞安好医药科技
- Start
- Jun 2021
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DX1002 in hepatocellular carcinoma (HCC), gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by 东莞安好医药科技. Started Jun 2021; status: active.
02
Drugs
DX1002
03
Conditions
hepatocellular carcinoma (HCC)gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20200996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200996.